BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 25246112)

  • 1. Ovarian reserve in breast cancer: assessment with anti-Müllerian hormone.
    Hamy AS; Porcher R; Cuvier C; Giacchetti S; Schlageter MH; Coussieu C; Gronier H; Feugeas JP; Adoui N; Lacorte JM; Poirot C; Habdous M; Espié M
    Reprod Biomed Online; 2014 Nov; 29(5):573-80. PubMed ID: 25246112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pretreatment anti-Müllerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancer.
    Anderson RA; Rosendahl M; Kelsey TW; Cameron DA
    Eur J Cancer; 2013 Nov; 49(16):3404-11. PubMed ID: 23968732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-müllerian hormone levels and evolution in women of reproductive age with breast cancer treated with chemotherapy.
    Fréour T; Barrière P; Masson D
    Eur J Cancer; 2017 Mar; 74():1-8. PubMed ID: 28135602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting Ovarian Activity in Women Affected by Early Breast Cancer: A Meta-Analysis-Based Nomogram.
    Barnabei A; Strigari L; Marchetti P; Sini V; De Vecchis L; Corsello SM; Torino F
    Oncologist; 2015 Oct; 20(10):1111-8. PubMed ID: 26341758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of adjuvant chemotherapy on anti-Müllerian hormone in women below 35 years treated for early breast cancer.
    Perdrix A; Saint-Ghislain M; Degremont M; David M; Khaznadar Z; Loeb A; Leheurteur M; Di Fiore F; Clatot F
    Reprod Biomed Online; 2017 Oct; 35(4):468-474. PubMed ID: 28652099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective effect of goserelin on ovarian reserve during (neo)adjuvant chemotherapy in young breast cancer patients: a prospective cohort study in China.
    Wang S; Pei L; Hu T; Jia M; Wang S
    Hum Reprod; 2021 Mar; 36(4):976-986. PubMed ID: 33411897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Anti-Müllerian hormone as a new marker of the ovarian reserve function preservation by goserelin during (neo)adjuvant chemotherapy for young breast cancer patients].
    Wang SY; Wang S
    Beijing Da Xue Xue Bao Yi Xue Ban; 2019 Jun; 51(3):536-541. PubMed ID: 31209428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The utility of anti-Müllerian hormone in the diagnosis and prediction of loss of ovarian function following chemotherapy for early breast cancer.
    Anderson RA; Mansi J; Coleman RE; Adamson DJA; Leonard RCF
    Eur J Cancer; 2017 Dec; 87():58-64. PubMed ID: 29117576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-Müllerian hormone (AMH) levels in premenopausal breast cancer patients treated with taxane-based adjuvant chemotherapy - A translational research project of the SUCCESS A study.
    Trapp E; Steidl J; Rack B; Kupka MS; Andergassen U; Jückstock J; Kurt A; Vilsmaier T; de Gregorio A; de Gregorio N; Tzschaschel M; Lato C; Polasik A; Tesch H; Schneeweiss A; Beckmann MW; Fasching PA; Janni W; Müller V
    Breast; 2017 Oct; 35():130-135. PubMed ID: 28732324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective evaluation of serum anti-Müllerian hormone dynamics in 250 women of reproductive age treated with chemotherapy for breast cancer.
    Dezellus A; Barriere P; Campone M; Lemanski C; Vanlemmens L; Mignot L; Delozier T; Levy C; Bendavid C; Debled M; Bachelot T; Jouannaud C; Loustalot C; Mouret-Reynier MA; Gallais-Umbert A; Masson D; Freour T
    Eur J Cancer; 2017 Jul; 79():72-80. PubMed ID: 28463758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pretreatment serum anti-müllerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer.
    Anderson RA; Cameron DA
    J Clin Endocrinol Metab; 2011 May; 96(5):1336-43. PubMed ID: 21325458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced ovarian reserve in young early breast cancer patients: preliminary data from a prospective cohort trial.
    Wenners A; Grambach J; Koss J; Maass N; Jonat W; Schmutzler A; Mundhenke C
    BMC Cancer; 2017 Sep; 17(1):632. PubMed ID: 28877720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum anti-müllerian hormone levels in evaluation of chemotherapy effect on ovarian reserve in women with breast cancer. A follow-up study.
    Al-Rawi SA; Saleh BO; Al-Naqqash MA
    Saudi Med J; 2018 Jul; 39(7):733-735. PubMed ID: 29968900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ovarian reserve after treatment with alkylating agents during childhood.
    Thomas-Teinturier C; Allodji RS; Svetlova E; Frey MA; Oberlin O; Millischer AE; Epelboin S; Decanter C; Pacquement H; Tabone MD; Sudour-Bonnange H; Baruchel A; Lahlou N; De Vathaire F
    Hum Reprod; 2015 Jun; 30(6):1437-46. PubMed ID: 25801499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Five-year study assessing the clinical utility of anti-Müllerian hormone measurements in reproductive-age women with cancer.
    Palinska-Rudzka KE; Ghobara T; Parsons N; Milner J; Lockwood G; Hartshorne GM
    Reprod Biomed Online; 2019 Oct; 39(4):712-720. PubMed ID: 31471141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toward a better follow-up of ovarian recovery in young women after chemotherapy with a hypersensitive antimüllerian hormone assay.
    Decanter C; Peigne M; Mailliez A; Morschhauser F; Dassonneville A; Dewailly D; Pigny P
    Fertil Steril; 2014 Aug; 102(2):483-7. PubMed ID: 24951363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prechemotherapy antimullerian hormone, age, and body size predict timing of return of ovarian function in young breast cancer patients.
    Su HC; Haunschild C; Chung K; Komrokian S; Boles S; Sammel MD; DeMichele A
    Cancer; 2014 Dec; 120(23):3691-8. PubMed ID: 25081546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of Anti-Mullerian Hormone Levels, Antral Follicle Counts, and Mean Ovarian Volumes in Chemotherapy-Induced Amenorrhea among Breast Cancer Patients: A Prospective Clinical Study.
    Ünal Ç; Ordu Ç; Özmen T; İlgun AS; Çelebi F; Baysal B; Özkurt E; Duymaz T; Erdoğan İyigün Z; Kurt S; Öztürk MA; Pilancı KN; Alço G; Yararbaş K; Kayan Tapan T; Güven DC; Soybir G; Özmen V
    Curr Oncol; 2023 Oct; 30(10):9217-9229. PubMed ID: 37887566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Different patterns of ovarian recovery after cancer treatment suggest various individual ovarian susceptibilities to chemotherapy.
    Decanter C; Cloquet M; Dassonneville A; D'Orazio E; Mailliez A; Pigny P
    Reprod Biomed Online; 2018 Jun; 36(6):711-718. PubMed ID: 29523398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Undetectable antimüllerian hormone levels and recovery of chemotherapy-induced ovarian failure in women with breast cancer on an oral aromatase inhibitor.
    Dieudonné AS; Vandenberghe J; Geerts I; Billen J; Paridaens R; Wildiers H; Neven P
    Menopause; 2011 Jul; 18(7):821-4. PubMed ID: 21326118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.